WellCare Health Plans expands Medicaid benefits to members in Georgia

Health insurance company WellCare Health Plans enhanced its Medicaid benefits this week for members who live in Georgia as a way to encourage them to maintain healthier lives.

WellCare, headquartered in Tampa, Fla., expanded benefits by adding new incentives to its healthy rewards program and increasing over-the-counter and vision program benefits, according to a statement from the company.

"Our enhanced benefits are designed to positively impact the health of our Georgia Medicaid members and ultimately can help to reduce the long-term costs of health care," said Roman Kulich, WellCare's region president of Georgia and South Carolina, in a statement.

WellCare serves more than 640,000 people in Georgia and about 3.7 million people in the U.S.

In its healthy rewards program, WellCare now provides $50 gifts to patients who meet health goals. Members also receive a 20 percent increase in credit toward over-the-counter supplies like cold medicine and vitamins.

Additionally, members will get a $50 credit toward a pair of eyeglasses as part of WellCare’s vision plan, among other optometry benefits.

WellCare of Georgia Medicaid members will continue to have access to WellCare’s existing benefits like free cell phones for high-risk pregnancy patients, free General Education Development testing and a free smartphone app that allows users to keep track of their benefits and appointments.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.